Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 13/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 12/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 11/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.46 |
| ▸ | RORC | P51449 | 3/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2513034 | 0.87 | SLC6A4 (0.48) | SLC6A3SLC6A4SLC6A2CYP2D6KCNH2 | |
| SCHEMBL6995560 | 0.84 | SLC6A4 (0.59) | SLC6A3SLC6A4SLC6A2CYP2D6KCNH2 | |
| SCHEMBL8883768 | 0.84 | SLC6A2 (0.52) | SLC6A3SLC6A4SLC6A2CYP2D6KCNH2 | |
| SCHEMBL6996455 | 0.83 | SLC6A2 (0.51) | SLC6A3SLC6A4SLC6A2CYP2D6KCNH2 | |
| SCHEMBL6993234 | 0.83 | SLC6A4 (0.56) | SLC6A3SLC6A4SLC6A2CYP2D6KCNH2 | |
| SCHEMBL7956363 | 0.83 | SLC6A4 (0.49) | SLC6A3SLC6A4SLC6A2CYP2D6RORC | |
| Hydrochloric Acid SCHEMBL6991487 | 0.82 | SLC6A2 (0.50) | SLC6A3SLC6A4SLC6A2CYP2D6KCNH2 | |
| Hydrochloric Acid SCHEMBL7000511 | 0.82 | SLC6A4 (0.54) | SLC6A3SLC6A4SLC6A2CYP2D6KCNH2 | |
| SCHEMBL6990421 | 0.81 | SLC6A2 (0.49) | SLC6A3SLC6A4SLC6A2CYP2D6KCNH2 | |
| SCHEMBL6992309 | 0.80 | SLC6A2 (0.49) | SLC6A3SLC6A4SLC6A2CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0920425-B1 | SUBSTITUTED 4-(1H-BENZIMIDAZOL-2-YL-AMINO)PIPERIDINES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | AVENTIS PHARMA INC (US) | 2003-02-19 | — | — | EP | disclosed |
| CN-1098264-C | Substituted 4- (1H-benzimidazol-2-yl-amino) piperidines for the treatment of allergic diseases | AVENTIS PHARMA INC (US) | 2003-01-08 | — | — | CN | disclosed |
| EP-0874843-B1 | SUBSTITUTED 4-(1H-BENZIMIDAZOL-2-YL) 1,4]DIAZEPANES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | AVENTIS PHARMA INC (US) | 2002-08-07 | — | — | EP | disclosed |
| US-6423704-B2 | CROHN'S DISEAS, ANTIULCER AGENTS, ASTHMA, EMESIS | AVENTIS PHARMACEUTICALS INC. | 2002-07-23 | — | — | US | disclosed |
| CN-1080262-C | Novel substituted 4-(1H-benzimidazol-2-YL) [1,4] diazepanes useful for the treatment of allergic diseases | HOECHST MARION ROUSSEL INC (US) | 2002-03-06 | — | — | CN | disclosed |
| US-6329392-B1 | ANTIALLERGENS | AVENTIS PHARMACEUTICALS, INC. | 2001-12-11 | — | — | US | disclosed |
| US-20010034343-A1 | Novel substituted 4-(1H-benzimidazol-2-yl) [1,4]diazepanes useful for the treatment of allergic diseases | AVENTIS PHARMACEUTICALS INC. | 2001-10-25 | — | — | US | disclosed |
| CN-1067385-C | Novel substituted piperidines useful for the treatment of allergic diseases | MERRELL DOW PHARMA (US) | 2001-06-20 | — | — | CN | disclosed |
| US-6211199-B1 | HISTAMINE AND TACHYKININ RECEPTOR ANTAGONISTS; ANTIASTHMATICS, ANTIEMETICS; RESPIRATORY SYSTEM DISORDERS, INFLAMMATORY BOWEL DISEASE, CONJUNCTIVITIS | AVENTIS PHARMACEUTICALS INC. | 2001-04-03 | — | — | US | disclosed |
| US-6194406-B1 | HISTAMINE RECEPTOR ANTAGONISTS; TACHYKININ RECEPTOR ANTAGONISTS; ASTHMA; BRONCHITIS; INFLAMMATORY BOWEL DISEASES, INCLUDING CROHN'S DISEASE AND ULCERATIVE COLITIS; SEASONAL RHINITIS; SINUSITIS; ANTIALLERGENS; EMETIC AGENTS | AVENTIS PHARMACEUTICALS INC. | 2001-02-27 | — | — | US | disclosed |
| EP-0777666-B1 | SUBSTITUTED PIPERIDINES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | MERRELL PHARMA INC (US) | 1999-03-03 | — | — | EP | disclosed |
| CN-1207097-A | Novel substituted 4- (1H-benzimidazol-2-yl) [1,4] diazepanes useful for the treatment of allergic diseases | HOECHST MARION ROUSSEL INC (US) | 1999-02-03 | — | — | CN | disclosed |
| CN-1202894-A | Substituted 4-(1H-benzimidzol-2-yl-amino) piepridines useful for the treatment of allergic diseases | HOECHST MARION ROUSSEL INC (US) | 1998-12-23 | — | — | CN | disclosed |
| EP-0874843-A1 | NOVEL SUBSTITUTED 4-(1H-BENZIMIDAZOL-2-YL) 1,4]DIAZEPANES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | HOECHST MARION ROUSSEL, INC. (US) | 1998-11-04 | — | — | EP | disclosed |
| US-5824690-A | TREATING ASTHMA, COUGH | HOECHST MARION ROUSSEL INC. (US) | 1998-10-20 | — | — | US | disclosed |
| CN-1158612-A | Novel substituted piperidines for the treatment of allergic diseases | MERRELL DOW PHARMA (US) | 1997-09-03 | — | — | CN | disclosed |
| WO-1997022604-A1 | NOVEL SUBSTITUTED 4-(1H-BENZIMIDAZOL-2-YL)[1,4]DIAZEPANES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | HOECHST MARION ROUSSEL, INC. (US) | 1997-06-26 | — | — | WO | disclosed |
| EP-0777666-A1 | NOVEL SUBSTITUTED PIPERIDINES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | MERRELL PHARMACEUTICALS INC. (US) | 1997-06-11 | — | — | EP | disclosed |
| WO-1997019074-A1 | SUBSTITUTED 4-(1H-BENZIMIDAZOL-2-YL-AMINO)PIPERIDINES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | HOECHST MARION ROUSSEL, INC. (US) | 1997-05-29 | — | — | WO | disclosed |
| WO-1996006094-A1 | NOVEL SUBSTITUTED PIPERIDINES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | MERRELL PHARMACEUTICALS INC. (US) | 1996-02-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034343-A1 | Novel substituted 4-(1H-benzimidazol-2-yl) [1,4]diazepanes useful for the treatment of allergic diseases | HRH4, HRH2, HRH1 | SLC6A3 3128/4885SLC6A4 1652/4885SLC6A2 3664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.